Seminars in Nephrology
Volume 24, Issue 2 , Pages 141-146 , March 2004

Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning?

  • Reza Abdi

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Reza Abdi, MD, Renal Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115-6392 USA
    • Renal Division, Brigham and Women’s Hospital, Boston, MA, USA
    • ,
  • Barry M Brenner

      Affiliations

    • Renal Division, Brigham and Women’s Hospital, Boston, MA, USA

References 

  1. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons (A potentially adverse response to renal ablation). Am J Physiol. 1981;241:F85–F93
  2. Sugimoto H, Shikata K, Matsuda M, et al.  Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia. 1998;41:1426–1434
  3. Mattar AL, Fujihara CK, Ribeiro MO, de Nucci G, Zatz R. Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. Nephron. 1996;74:136–143
  4. Danielson LA, Conrad KP. Prostaglandins maintain renal vasodilation and hyperfiltration during chronic nitric oxide synthase blockade in conscious pregnant rats. Circ Res. 1996;79:1161–1166
  5. Anderson S, Brenner BM. Pathogenesis of diabetic glomerulopathy (hemodynamic considerations). Diabetes Metab Rev. 1988;4:163–177
  6. Uriu K, Kaizu K, Qie YL, Kai K, Eto S. Effect of acute thromboxane A2 inhibition on the renal hemodynamics in a spontaneously non-insulin-dependent diabetic rat, Otsuka Long-Evans Tokushima Fatty rat. J Diabetes Complications. 1999;13:182–186
  7. Rennke HG. Glomerular adaptations to renal injury or ablation. Role of capillary hypertension in the pathogenesis of progressive glomerulosclerosis. Blood Purif. 1988;6:230–239
  8. Nagata M, Scharer K, Kriz W. Glomerular damage after uninephrectomy in young rats. I. Hypertrophy and distortion of capillary architecture. Kidney Int. 1992;42:136–147
  9. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int. 1992;42:148–160
  10. Olson JL, Hostetter TH, Rennke HG, Brenner BM, Venkatachalam MA. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int. 1982;22:112–126
  11. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest. 1995;96:953–964
  12. Johnson RJ, Alpers CE, Yoshimura A, et al.  Renal injury from angiotensin II-mediated hypertension. Hypertension. 1992;19:464–474
  13. Taal MW, Zandi-Nejad K, Weening B, et al.  Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int. 2000;58:1664–1676
  14. Floege J, Burns MW, Alpers CE, et al.  Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int. 1992;41:297–309
  15. Ziai F, Nagano H, Kusaka M, et al.  Renal allograft protection with losartan in Fisher-Lewis rats (Hemodynamics, macrophages, and cytokines). Kidney Int. 2000;57:2618–2625
  16. Johnson RJ, Floege J, Couser WG, Alpers CE. Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol. 1993;4:119–128
  17. Miyatake N, Shikata K, Sugimoto H, et al.  Intercellular adhesion molecule 1 mediates mononuclear cell infiltration into rat glomeruli after renal ablation. Nephron. 1998;79:91–98
  18. Ruiz-Ortega M, Ruperez M, Lorenzo O, et al.  Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl. 2002;82:12–22
  19. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol. 1998;161:430–439
  20. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res. 1999;84:695–703
  21. Cortes P, Riser BL, Zhao X, Narins RG. Glomerular volume expansion and mesangial cell mechanical strain (mediators of glomerular pressure injury). Kidney Int Suppl. 1994;45:S11–S16
  22. Cortes P, Zhao X, Riser BL, Narins RG. Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy. Kidney Int. 1997;51:57–68
  23. Harris RC, Akai Y, Yasuda T, Homma T. The role of physical forces in alterations of mesangial cell function. Kidney Int Suppl. 1994;45:S17–S21
  24. Riser BL, Cortes P, Heilig C, et al.  Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol. 1996;148:1915–1923
  25. Riser BL, Varani J, Cortes P, Yee J, Dame M, Sharba AK. Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence (a possible new mechanism for glomerulosclerosis). Am J Pathol. 2001;158:11–17
  26. Deen WM, Bohrer MP, Brenner BM. Macromolecule transport across glomerular capillaries (application of pore theory). Kidney Int. 1979;16:353–365
  27. Deen WM, Bohrer MP, Robertson CR, Brenner BM. Determinants of the transglomerular passage of macromolecules. Fed Proc. 1977;36:2614–2618
  28. Olson JL, de Urdaneta AG, Heptinstall RH. Glomerular hyalinosis and its relation to hyperfiltration. Lab Invest. 1985;52:387–398
  29. Oliver JD, Simons JL, Troy JL, Provoost AP, Brenner BM, Deen WM. Proteinuria and impaired glomerular permselectivity in uninephrectomized fawn-hooded rats. Am J Physiol. 1994;267:F917–F925
  30. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925–1930
  31. Zatz R, Anderson S, Meyer TW, Dunn BR, Rennke HG, Brenner BM. Lowering of arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes. Kidney Int Suppl. 1987;20:S123–S129
  32. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease (A systematic overview of randomized placebo-controlled trials). Am J Kidney Dis. 2000;35:695–707
  33. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–1462
  34. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow- up study. Arch Intern Med. 1996;156:286–289
  35. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes (a meta-regression analysis). Ann Intern Med. 1993;118:129–138
  36. Lewis EJ, Hunsicker LG, Clarke WR, et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  37. Brenner BM, Cooper ME, de Zeeuw D, et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  38. Maschio G, Alberti D, Janin G, et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–945
  39. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril (REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy). Lancet. 1998;352:1252–1256
  40. Ruggenenti P, Perna A, Gherardi G, et al.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–364
  41. Paul LC. Chronic allograft nephropathy (An update). Kidney Int. 1999;56:783–793
  42. Abdi R, Slakey D, Kittur D, Burdick J, Racusen L. Baseline glomerular size as a predictor of function in human renal transplantation. Transplantation. 1998;66:329–333
  43. Azuma H, Nadeau K, Mackenzie HS, Brenner BM, Tilney NL. Nephron mass modulates the hemodynamic, cellular, and molecular response of the rat renal allograft. Transplantation. 1997;63:519–528
  44. Nadasdy T, Abdi R, Pitha J, Slakey D, Racusen L. Diffuse glomerular basement membrane lamellation in renal allografts from pediatric donors to adult recipients. Am J Surg Pathol. 1999;23:437–442
  45. Terasaki PI, Koyama H, Cecka JM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation. 1994;57:1450–1454
  46. Abdi R, Tran TB, Zee R, Brenner BM, Milford EL. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation. 2001;72:726–729
  47. Lin J, Valeri AM, Markowitz GS, D’Agati VD, Cohen DJ, Radhakrishnan J. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation. 2002;73:783–788

PII: S0270-9295(03)00194-3

doi: 10.1016/j.semnephrol.2003.11.004

Seminars in Nephrology
Volume 24, Issue 2 , Pages 141-146 , March 2004

Article Tools

* Image Usage & Resolution